{
    "2018-06-12": [
        [
            {
                "time": "2018-06-13",
                "original_text": "AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Phase 3 Studies",
                        "Rheumatoid Arthritis",
                        "EULAR 2018"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}